Immuneering Corp (IMRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Immuneering reported revenue of $0. Net income was -$56.0M, or -$1.27 per diluted share. Operating activities generated -$45.3M of cash, leaving -$45.5M of free cash flow. At fiscal year end, Immuneering held $232.0M in total assets against $13.5M in total liabilities, including $128.6M of cash and equivalents.
Open the full interactive Immuneering financials → Quarterly statements, key ratios, valuation history and price charts.
Immuneering Key Stats
| Share Price | $3.56 |
|---|---|
| Market Cap | $230.3M |
| 52-Week Range | $3.56 – $8.33 |
| Shares Outstanding | 64.7 million (basic, 2026 Q2) |
Immuneering Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $316,952 | $0 | $0 | $0 |
| Gross Profit | $926,888 | $158,830 | $0 | — | — |
| Operating Income | -$33.9M | -$51.7M | -$58.4M | -$64.1M | -$59.4M |
| Pre-Tax Income | -$33.8M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Income Tax | -$307,485 | — | — | — | $0 |
| Net Income | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Diluted EPS | -$2.46 | -$1.90 | -$1.88 | -$2.04 | -$1.27 |
Immuneering Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$15.0M | -$11.6M | -$13.5M | -$17.3M |
| Diluted EPS | -$0.38 | -$0.26 | -$0.21 | -$0.27 |
Immuneering Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $74.9M | $72.6M | $59.4M | $36.1M | $128.6M |
| Current Assets | $152.3M | $108.7M | $89.1M | $39.6M | $176.2M |
| Total Assets | $166.7M | $122.4M | $102.6M | $52.7M | $232.0M |
| Current Liabilities | $5.6M | $8.1M | $7.8M | $7.5M | $10.1M |
| Total Liabilities | $10.7M | $12.5M | $12.0M | $11.3M | $13.5M |
| Shareholders' Equity | $156.0M | $109.9M | $90.6M | $41.4M | $218.5M |
Immuneering Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$30.9M | -$44.1M | -$49.0M | -$55.0M | -$45.3M |
| Cash From Investing | -$75.6M | $41.8M | $7.3M | $26.4M | -$88.7M |
| Cash From Financing | $144.3M | $19,004 | $28.4M | $5.3M | $226.6M |
| Free Cash Flow | -$30.9M | -$44.8M | -$49.3M | -$55.1M | -$45.5M |
Figures from Immuneering's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immuneering financials page for every line item.
Immuneering Company Profile
| Ticker | IMRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001790340 |
Frequently Asked Questions
What was Immuneering's revenue in fiscal 2025?
Immuneering (IMRX) reported revenue of $0 for fiscal 2025.
What is Immuneering's annual revenue history?
Immuneering's annual revenue by fiscal year: 2021: $2.1M; 2022: $316,952; 2023: $0; 2024: $0; 2025: $0.
What was Immuneering's net income in fiscal 2025?
Immuneering reported net income of -$56.0M for fiscal 2025.
What was Immuneering's earnings per share (EPS) in fiscal 2025?
Immuneering's diluted EPS was -$1.27 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Immuneering generate in fiscal 2025?
Immuneering generated -$45.5M of free cash flow in fiscal 2025.
What was Immuneering's revenue last quarter?
In its most recent reported quarter (2026 Q2), Immuneering reported revenue of $0.
How many shares of Immuneering are outstanding?
Immuneering reported a weighted average of 64.7 million basic shares outstanding in 2026 Q2.
What is Immuneering's market cap?
Based on its latest closing price, Immuneering (IMRX) has a market capitalization of about $230.3M.
When does Immuneering's fiscal year end?
Immuneering's fiscal year end, as registered with the SEC, is December 31.
Where is Immuneering headquartered?
Immuneering lists its business address in Cambridge, Massachusetts in its SEC filings.